PHOTOCHLOR AND DVDMS
CHINA'S DOMESTICALLY DEVELOPED PHOTOSENSITISERS
China's PDT programme is not limited to imported Photofrin. Two domestically developed photosensitisers โ DVDMS (sinoporphyrin sodium) and Photochlor โ offer meaningful improvements over first-generation agents and underpin China's unique clinical trial programme combining PDT with immunotherapy.
analyticsAt a Glance
- check_circleDVDMS (sinoporphyrin sodium): China's most clinically advanced domestic photosensitiser
- check_circleShorter photosensitivity than Photofrin; superior singlet oxygen generation; stronger immunogenic cell death
- check_circleUsed clinically for NPC recurrence, head and neck cancers, and in PDT+immunotherapy trials
- check_circlePhotochlor (HPPH): chlorin-based second-generation agent with 2-week photosensitivity
Why China Developed Its Own Photosensitisers
Photofrin is effective but has well-known limitations โ prolonged photosensitivity, complex chemical composition, and supply dependency on foreign manufacturers. Chinese researchers and the pharmaceutical industry invested in developing improved second-generation agents tailored to China's cancer burden and clinical priorities.
โDVDMS was developed specifically to address what Photofrin cannot: shorter photosensitivity, better singlet oxygen generation, and stronger immune activation โ properties that matter enormously when combining PDT with immunotherapy.โ
Photofrin's Limitations That Drove Development
The 4โ6 week photosensitivity after Photofrin injection severely limits patient quality of life and compliance. Photofrin is a heterogeneous mixture โ not a single pure molecule โ making pharmacokinetic behaviour less predictable than desirable. Its activation at 630 nm allows only modest tissue penetration (~5โ7 mm). Chinese PDT research sought agents with shorter photosensitivity, greater purity, and stronger photodynamic activity.
The Strategic Value of Domestic Innovation
For China's PDT programme to scale and incorporate combinations with China's domestically approved checkpoint inhibitors (sintilimab, camrelizumab, tislelizumab), having China-approved photosensitisers with regulatory pathways that match China's drug approval process is strategically essential. DVDMS is manufactured in China, priced for the Chinese market, and undergoing Chinese regulatory approval โ enabling combination trials that cannot occur with imported Photofrin alone.
Photosensitiser Comparison: Photofrin vs DVDMS vs Photochlor
Key properties of the three photosensitisers relevant to clinical use in China.
| Property | Photofrin (Porfimer Sodium) | DVDMS (Sinoporphyrin Sodium) | Photochlor (HPPH) |
|---|---|---|---|
| Chemical Class | Hematoporphyrin derivative (mixture) | Porphyrin monomer (pure compound) | Chlorin e6 derivative (pure compound) |
| Activation Wavelength | 630 nm | 630 nm (similar to Photofrin) | 665 nm (deeper tissue penetration) |
| Tissue Penetration | 5โ7 mm | 5โ8 mm (slightly better) | 8โ12 mm (chlorins penetrate deeper) |
| Singlet Oxygen Generation | Moderate | High โ approximately 2ร Photofrin | High |
| Photosensitivity Duration | 4โ6 weeks (full body) | 1โ3 weeks (shorter clearance) | 2 weeks |
| Chemical Purity | Heterogeneous mixture | Single pure compound | Single pure compound |
| ICD / Immune Activation | Moderate | Stronger ICD signals; better for combo with ICI | Under investigation |
| NMPA Regulatory Status | Approved (Photofrin imported) | Clinical trials; conditional approval pathway | Clinical use; approval ongoing |
| Availability in China | Available at PDT centres | Available at trial centres and selected clinical programmes | Available at selected centres |
DVDMS in Clinical Practice
DVDMS (sinoporphyrin sodium, also written as DVDMS-3Na or Zn-BPS in some publications) has moved from the laboratory to clinical practice at major Chinese cancer centres. Its use spans both established PDT indications and novel combination approaches.
NPC Recurrence: DVDMS vs Photofrin
At Sun Yat-sen University Cancer Center, DVDMS is increasingly used alongside Photofrin for endoscopic PDT of locally recurrent nasopharyngeal carcinoma. The shorter photosensitivity duration (1โ3 weeks vs 4โ6 weeks for Photofrin) is a meaningful quality-of-life advantage for NPC patients managing an already demanding post-radiation clinical situation.
Head and Neck Cancer: The Core Clinical Indication
Endoscopic PDT for head and neck mucosal recurrences โ oropharynx, hypopharynx, larynx โ using DVDMS is performed at several Chinese academic centres. Published case series and small institutional studies demonstrate response rates comparable to Photofrin with better patient-reported photosensitivity experience.
PDT + Immunotherapy Trials: DVDMS as the Preferred Agent
DVDMS has become the preferred photosensitiser for Chinese PDT + immunotherapy combination trials โ specifically because its stronger singlet oxygen generation and enhanced immunogenic cell death signalling make it better-suited to the combination than Photofrin. The ICD enhancement is directly relevant to the mechanism of synergy with checkpoint inhibitors.
Ongoing Research: Optimisation Studies
Chinese researchers are actively optimising DVDMS dosing, drug-to-light intervals, and combination schedules with immunotherapy. Several studies are investigating whether different DVDMS doses produce differential immunogenic vs cytotoxic effects โ with implications for maximising the immunotherapy synergy vs direct tumour kill.
Photochlor (HPPH): The Chlorin-Based Alternative
Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a, commonly known by its research name HPPH) is a second-generation chlorin photosensitiser developed initially in the US and subsequently used in selected Chinese programmes.
Photochlor's Key Advantages
Activation at 665 nm โ deeper red light than Photofrin's 630 nm โ provides meaningfully better tissue penetration (8โ12 mm vs 5โ7 mm for Photofrin). This deeper activation is valuable for thicker tumours or those where light delivery access is not perfectly positioned. Photosensitivity duration is approximately 2 weeks โ shorter than Photofrin but longer than DVDMS.
Clinical Use in China
Photochlor is used at selected Chinese centres for head and neck, oesophageal, and lung PDT indications. It has not achieved the same breadth of Chinese clinical programme as DVDMS. Phase I/II data from Chinese centres shows safety and preliminary efficacy comparable to Photofrin with the photosensitivity advantage. The 665 nm activation may provide advantages for larger tumours or less accessible anatomical sites.
Explore the PDT Knowledge Base
Related PDT topics and resources.
- What Is Photodynamic Therapy and How Does It Work?
- Photofrin (Porfimer Sodium): The Most Widely Approved Photosensitiser
- PDT Combined with Immunotherapy: Science and China's Trials
- PDT for Nasopharyngeal Carcinoma Recurrence: China's Expertise
- China MWA Innovation: Advanced Antenna Systems and Outcomes
- Photodynamic Therapy โ Full Treatment Page
Frequently Asked Questions
Common questions about DVDMS, Photochlor, and Chinese photosensitiser innovation.
About the Agents
Is DVDMS better than Photofrin for all PDT indications?
Not necessarily for all indications. DVDMS is superior to Photofrin in specific properties: shorter photosensitivity duration, stronger singlet oxygen generation, better immunogenic cell death signalling, and greater chemical purity. These advantages are most clinically meaningful for: (1) patients who value shorter photosensitivity restrictions, (2) combination with immunotherapy where ICD enhancement matters, and (3) research applications requiring pharmacokinetic precision. For standard palliative PDT of oesophageal or biliary tumours where response rate and light delivery access are the primary drivers, the differences may be less clinically decisive. Centre expertise with the specific agent is also an important factor.
Can I specifically request DVDMS rather than Photofrin for my PDT?
DVDMS availability depends on the treating centre and whether you are enrolling in a clinical trial or accessing it through an established clinical programme. At Chinese centres where DVDMS is used routinely (primarily for NPC and head and neck cancers), patients can specifically request it in consultation with the treating team. For most Western centres, DVDMS is not available โ only Photofrin and ALA/MAL are in standard clinical use. CancerFax identifies Chinese centres offering DVDMS for appropriate indications.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want Access to China's Advanced PDT Photosensitisers?
Upload your medical records and our team will assess whether DVDMS-based PDT at a Chinese centre is appropriate for your cancer type and treatment history โ including combination with immunotherapy in clinical trials.
For informational purposes only. Photosensitiser choice and PDT protocol require evaluation by qualified oncology and PDT specialists.